NeuroOne Medical Technologies Corporation has appointed David Wambeke as Chief Business Officer, with the executive simultaneously purchasing 1,000,000 shares of company stock at $0.6704 per share. This dual announcement represents a significant vote of confidence in the medical technology company's strategic direction and growth potential in the neurological disorder treatment market.
Wambeke will lead NeuroOne's drug delivery program and work closely with the executive team to advance clinical development and commercialization strategy. His responsibilities include refining product requirements for preclinical and clinical-stage devices, expanding relationships with key opinion leaders in targeted disease areas, and engaging prospective pharmaceutical partners to maximize the strategic value of the company's emerging drug delivery platform. He will also oversee investor relations and support strategic business development initiatives including partnerships and corporate transactions.
The appointment brings substantial healthcare leadership experience to NeuroOne. Wambeke most recently served as Chief Business Officer at DiaMedica Therapeutics, where he led the strategic expansion of the company's lead biologic into preeclampsia, establishing and overseeing a first-in-pregnancy Phase 2 clinical trial that delivered positive results. Prior to DiaMedica, he spent approximately 16 years at Craig-Hallum Capital Group in life sciences investment banking, advising public and private healthcare companies on equity financings, mergers and acquisitions, and strategic transactions.
"David brings a rare combination of public company experience, capital markets expertise, and a demonstrated ability to translate strategic vision into operational and clinical execution," said Dave Rosa, CEO of NeuroOne. "As we continue to execute on our strategy and expand awareness of NeuroOne's technology platform, we believe David will be instrumental in sharpening our messaging, deepening investor engagement, and advancing business development activities that support long-term value creation."
The personal investment component of this announcement carries particular significance in the healthcare technology sector. Wambeke's purchase of 1 million shares represents a substantial personal commitment that aligns his interests directly with shareholders. NeuroOne intends to use the net proceeds from this sale to support ongoing clinical and product development activities, as well as for working capital and general corporate purposes. This transaction occurs as the company continues to scale commercialization across cleared indications including epilepsy and trigeminal nerve applications.
"I'm excited to join NeuroOne at such a pivotal moment and to meaningfully align myself with shareholders through my investment," said Wambeke. "With four FDA 510(k)-cleared devices and a strategic partnership with Zimmer Biomet, NeuroOne has validated its platform technology and established a strong commercial foundation. As the Company continues to scale commercialization across these cleared indications, I believe even greater opportunities lie ahead in basivertebral ablation, drug delivery, and spinal cord stimulation."
In connection with the appointment, NeuroOne granted Wambeke an inducement stock option to purchase 500,000 shares of common stock pursuant to the NeuroOne Medical Technologies Corporation 2021 Inducement Plan. The option has an exercise price of $0.6704 per share, equal to the closing price on the grant date, and a 10-year term with vesting over four years. This grant was approved by the company's compensation committee and represents a material inducement to his acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The significance of this executive appointment extends beyond leadership changes. For investors and the medical technology industry, it signals NeuroOne's commitment to advancing its platform technology while strengthening its business development capabilities. The company's focus on neurological disorders addresses a substantial market need, with its electrode technology platform offering combination diagnostic and therapeutic functions that could potentially reduce hospitalizations, lower costs, and improve patient outcomes. More information about the company's technology and approach is available at https://nmtc1.com.
For patients suffering from neurological disorders, this leadership development suggests continued advancement of NeuroOne's minimally invasive electrode technology platform. The company markets four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for brain applications, and OneRF Trigeminal Nerve Ablation System. These medical devices are restricted to sale by or on the order of a physician under federal law.
The combination of experienced leadership and substantial personal investment creates a compelling narrative for NeuroOne's future trajectory. As the company pursues research and development for drug delivery and spinal cord stimulation programs, this appointment positions it to better navigate the complex regulatory and commercialization landscape of neurological medical technology. The transaction underscores the growing importance of specialized leadership in healthcare technology companies seeking to translate innovative platforms into sustainable commercial success.
